CSIMarket
 

Healthcare Sector  




Data by Industry within Healthcare Sector


  Marketcap Revenues (TTM) Net Income (TTM) Employees
Industry (Millions) (Millions) (Millions) Number
Biotechnology & Pharmaceuticals Industry $ 557,280 $ 90,441 $ 3,925 76,397
Healthcare Facilities Industry $ 251,126 $ 212,163 $ 7,544 1,070,159
Major Pharmaceutical Preparations Industry $ 3,864,652 $ 674,026 $ 59,558 1,108,224
Medical Equipment & Supplies Industry $ 1,349,386 $ 304,389 $ 9,382 755,166
Medical Laboratories Industry $ 270,853 - $ 2,131 382,633
Laboratory Analytical Instruments Industry $ 145,976 $ 36,820 $ -50 65,904
In Vitro & In Vivo Diagnostic Substances Industry $ 98,000 $ 10,799 $ -184 19,244
Healthcare Sector $ 6,537,273 - $ 82,307 3,477,727
  Recent News from Healthcare Sector
Clinical Study

XORTX Therapeutics Inc.: Pioneering Hope for Progressive Kidney Disease Treatment

XORTX Therapeutics Inc.: A Promising Future for Progressive Kidney Disease TreatmentXORTX Therapeutics Inc. (XORTX), a leading clinical pharmaceutical company, has achieved significant milestones in 2023 and is poised to make even greater strides in 2024. With a strong focus on developing innovative therapies to combat progressive kidney disease, XORTX is...

Announcement

ObsEva Provides Board of Directors Update and Geneva Court Grants Temporary Moratorium

In a recent update, ObsEva, a leading biopharmaceutical company focused on women's reproductive health, announced changes to its Board of Directors. These developments, along with a subsequent court ruling, have significant implications for the company's future operations.ObsEva revealed that effective immediately, three new members have joined its Board ...

Financing Agreement

Madrigal Pharmaceuticals Leaps Forward with Upsized $600 Million Public Offering and Aims to Transform NASH Treatment Landscape

Madrigal Pharmaceuticals Announces Upsized $600 Million Public Offering and Record Net Loss
CONSHOHOCKEN, Pa., March 18, 2024 - Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL), a leading biopharmaceutical company specializing in novel therapeutics for nonalcoholic steatohepatitis (NASH), recently disclosed the pricing of its underwritten public offering...

Contract

Carlisle Companies to Expand Edge Metal Division with Acquisition of MTL Holdings

In a strategic move to expand its edge metal and non-insulated architectural wall systems business, Carlisle Companies Incorporated announced today its definitive agreement to acquire MTL Holdings from GreyLion Partners, a prominent private equity firm. The acquisition of MTL, a leading provider of pre-fabricated edge metal for commercial roofing systems,...

Personnel Announcements

Delcath Systems Strengthens Leadership with Appointment of Martha S. Rook as Chief Operating Officer

Delcath Systems Announces Martha S. Rook as New Chief Operating Officer
NEW YORK, March 18, 2024 - Delcath Systems, Inc., a leading interventional oncology company specializing in the treatment of primary and metastatic cancers of the liver, has recently appointed Martha S. Rook as its new Chief Operating Officer (COO). This strategic move is expected...

Financing Agreement

Outlook Therapeutics Closes Private Placement, Raising Up to $159 Million for Ophthalmic Bevacizumab Treatment



Iselin-based biopharmaceutical company, Outlook Therapeutics, has successfully concluded its private placement, securing upfront gross proceeds of approximately $60 million. In addition, the company has the potential to further bolster its financial position with up to $99 million upon the exercise of warrants issued in the private placement. Th...

Exagen Inc

Evanescence of Deficit: XGN Struggles with Weakness in Fourth Quarter Financial Report

Exagen Inc (Nasdaq: XGN) has shown significant signs of weakness in its latest financial report for the fourth quarter of 2023. Despite a decrease in the loss per share compared to the previous year, the company still reported a loss of $-0.30 per share. This is only a slight improvement from the loss of $-0.83 per share in the same period a year prior.

Leap Therapeutics Inc

Leap Therapeutics Inc Posts Operating Deficit of $14.82 Million in Latest Financial Report

Leap Therapeutics Inc, a major pharmaceutical preparations company, recently reported its financial results for the October to December 31, 2023 reporting season. While shareholders had not anticipated any significant changes, they were disappointed to observe an operating deficit of $14.82 million during this period. This represents a decline compared to...

Cyclo Therapeutics Inc

CYTH Sees Impressive Revenue Surge and Deficit Reduction in Q4 2023

Cyclo Therapeutics Inc, a Biotechnology and Pharmaceuticals company, has shown positive growth in the fourth quarter of 2023, despite industry-wide challenges. In its December 31, 2023 report, the company reported a significant revenue rise of 66.699% to $0.31 million. This increase in revenue has helped the company reduce its losses to $-0.18 per share, ...

Dividend

Homology Medicines Empowers Common Stockholders with Contingent Value Rights

Homology Medicines Declares Distribution to Common Stockholders
Homology Medicines, Inc. (Nasdaq: FIXX) has declared a distribution to its common stockholders of record as of March 21, 2024, granting them the right to receive one contingent value right (CVR) for each outstanding share of Homology common stock held. The payment date for this distributi...







Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com